Back to the main directory
EarningsReview / Equity
- A decent print, except for FCF by BNP Paribas Exane
- Itaú BBA on Energisa: Good 2Q22 Results by Itau
- Itaú BBA on Ser Educacional: Mixed 2Q22 Results by Itau
- Itaú BBA on Hapvida: Notes From 2Q22 Conference Call by Itau
- Path to margin improvement increasingly unclear by BNP Paribas Exane
- Itaú BBA on JHSF: Notes From 2Q22 Conference Call by Itau
- Zealand Pharma - Final countdown by Danske Bank Equity Research
- Netcompany - Maintained guidance requires solid H2 recovery by Danske Bank Equity Research
- Kamux - Growth continues but earnings under pressure by Danske Bank Equity Research
- Hexagon Composites ASA - Buy/NOK 40: Set for substantial long-term growth by Nordea
- Novozymes - Hold: Robust Q2 and hiked revenue guidance as expected by Nordea
- Olvi - Buy/EUR 42: Strong volume development continues by Nordea
- Sparebank 1 SR-Bank - Hold: Solid momentum but lagging behind peers by Nordea
- Smartoptics (Buy, TP: NOK26.00) - At an inflection point by DnB Markets
- Himalaya Shipping (Buy, TP: NOK82.00) - Impressive potential by DnB Markets
- Oncopeptides (Buy, TP: SEK55.00) - All the right moves by DnB Markets
- Rana Gruber (Buy, TP: NOK60.00) - Still-attractive iron ore prices by DnB Markets
- SpareBank1 Nord-Norge (Hold, TP: NOK102.00) - Exercising capital discipline by DnB Markets
- SpareBank 1 Østlandet (Hold, TP: NOK133.00) - Strong core revenues by DnB Markets
- Context Therapeutics - Anticipating a catalyst rich Q422 by Edison Investment Research
- JDC Group - FY22 guidance reiterated after strong Q222 by Edison Investment Research
- OpGen - Re-acceleration with momentum in the back half by Edison Investment Research
- Naturgy - 2Q22 Results: Underlying improvement, as expected; stock remains expensive; Underweight by JB Capital Markets
- Itaú BBA on Cosan: Positive 2Q22 With Record Adjusted EBITDA by Itau
- Citycon (Hold, TP: EUR7.70) - Post-Covid boost, as expected by DnB Markets